UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 729

Sortiert nach

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Clinical pharmacology and therapeutics, 2019-07, Vol.106 (1), p.94-102

2019

Link zum Volltext

Verfügbarkeit prüfen

Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

Journal of personalized medicine, 2018-04, Vol.8 (2), p.15

2018

Link zum Volltext

Verfügbarkeit prüfen

Introduction to Computational Modeling of Multicellular Tissues

Methods in molecular biology (Clifton, N.J.), 2022, Vol.2395, p.107

2022

Link zum Volltext

Verfügbarkeit prüfen

Modeling soil organic carbon evolution in long-term arable experiments with AMG model

Environmental modelling & software : with environment data news, 2019-08, Vol.118, p.99-113

2019

Link zum Volltext

Verfügbarkeit prüfen

The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites

Drug metabolism and disposition, 2020-11, Vol.48 (11), p.1113-1120

2020

Link zum Volltext

Verfügbarkeit prüfen

The logic of the floral transition: Reverse-engineering the switch controlling the identity of lateral organs

PLoS computational biology, 2017-09, Vol.13 (9), p.e1005744-e1005744

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation

International journal of molecular sciences, 2022-10, Vol.23 (20), p.12433

2022

Link zum Volltext

Verfügbarkeit prüfen

Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver

Drug metabolism and disposition, 2022-01, Vol.50 (1), p.24-32

2022

Link zum Volltext

Verfügbarkeit prüfen

The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity

Clinical pharmacology and therapeutics, 2022-03, Vol.111 (3), p.646-654

2022

Link zum Volltext

Verfügbarkeit prüfen

S10.3 - Use of ‘Virtual Children’ to inform exposure-controlled dosing of drugs in children

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S16-S16

Dinh, Jean C.

2020

Link zum Volltext

Verfügbarkeit prüfen

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities

Pharmaceutics, 2023-11, Vol.15 (11), p.2579

2023

Link zum Volltext

Verfügbarkeit prüfen

Is this the end for ranitidine? NDMA presence continues to confound

Clinical and translational science, 2021-07, Vol.14 (4), p.1197-1200

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children

Drug metabolism and disposition, 2016-07, Vol.44 (7), p.1070-1079

2016

Link zum Volltext

Verfügbarkeit prüfen

Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities

Paediatric drugs, 2020-02, Vol.22 (1), p.55-71

2020

Link zum Volltext

Verfügbarkeit prüfen

Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy

Children (Basel), 2019-02, Vol.6 (2), p.35

2019

Link zum Volltext

Verfügbarkeit prüfen

Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo

Drug metabolism and disposition, 2012-01, Vol.40 (1), p.54

2012

Link zum Volltext

Verfügbarkeit prüfen

P191 - The CYP2D6 ‘enhancer’ SNP: Long-range linkage analysis and impact on activity in human liver tissue

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S80-S81

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

Journal of clinical pharmacology, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research

Clinical pharmacology and therapeutics, 2015-09, Vol.98 (3), p.309-320

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity

Clinical pharmacology and therapeutics, 2023-11, Vol.114 (5), p.1033-1042

2023

Link zum Volltext

Verfügbarkeit prüfen

Selective deuteration of bupropion slows epimerization and reduces metabolism

Bioorganic & medicinal chemistry letters, 2022-11, Vol.76, p.129009-129009, Article 129009

2022

Link zum Volltext

Verfügbarkeit prüfen

Combining data on the bioavailability of midazolam and physiologically‐based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny

CPT: pharmacometrics and systems pharmacology, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

Clinical pharmacology and therapeutics, 2019-04, Vol.106 (1), p.94-102

2019

Link zum Volltext

Verfügbarkeit prüfen

Mathematical Modelling of the Floral Transition

Dinh, Jean-Louis T Q

2017

Link zum Volltext
ProQuest

Mathematical modelling of the floral transition

Dinh, Jean-Louis T. Q

2017

Link zum Volltext
ProQuest

1 – 25 von 729

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(600)
Mit Volltextzugriff
(662)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

Introduction to Computational Modeling of Multicellular Tissues

Modeling soil organic carbon evolution in long-term arable experiments with AMG model

The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites

The logic of the floral transition: Reverse-engineering the switch controlling the identity of lateral organs

Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation

Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver

The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity

S10.3 - Use of ‘Virtual Children’ to inform exposure-controlled dosing of drugs in children

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities

Is this the end for ranitidine? NDMA presence continues to confound

Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children

Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities

Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy

Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo

P191 - The CYP2D6 ‘enhancer’ SNP: Long-range linkage analysis and impact on activity in human liver tissue

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity

Selective deuteration of bupropion slows epimerization and reduces metabolism

Combining data on the bioavailability of midazolam and physiologically‐based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

Mathematical Modelling of the Floral Transition

Mathematical modelling of the floral transition

Suchergebnisse filtern